SEC Comment Letter for BIOCEPT INC (BIOCQ) (CIK 0001044378) — May 6, 2020
BIOCEPT INC (BIOCQ) (CIK 0001044378)
Date: May 6, 2020 · CIK: 0001044378 · Accession: 0000000000-20-003957
AI Filing Summary & Sentiment
File numbers found in text: 001-36284
Letter
United States securities and exchange commission logo May 6, 2020 Michael W. Nall President and Chief Executive Officer Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Re:Biocept, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 20, 2020 File No. 001-36284 Dear Mr. Nall: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Charles Bair
Show Raw Text
United States securities and exchange commission logo
May 6, 2020
Michael W. Nall
President and Chief Executive Officer
Biocept, Inc.
5810 Nancy Ridge Drive
San Diego, CA 92121
Re:Biocept, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 20, 2020
File No. 001-36284
Dear Mr. Nall:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Charles Bair